Plexcera Therapeutics, Icahn School of Medicine deal

The medical school granted Plexcera exclusive, worldwide rights to develop and commercialize recombinant human acid ceramidase (rhAC). Plexcera will evaluate rhAC to treat diseases caused by genetic ...